Pharmather CEO Chianelli – Ketamine

In Part #2 of our interview with Pharmather (CSE: PHRM) CEO Fabio Chianelli we discuss where they sit amongst their peers in the psychedelic space, and how they have carved out their niche in FDA approved type psychedelics like Ketamine.

We also talk about the importance of AI within the space and the data their development through their partnership with the UHN.

Pharmather Inc., is a wholly subsidiary of Newscope Capital Corporation and a specialty life sciences company that focuses on the research and development of psychedelic pharmaceuticals.

source